Endocrinology Book

http://www.fpnotebook.com/

SitagliptinAka: Januvia, DPP-4 Inhibitor, Dipeptidyl Peptidase-4 Inhibitor, DPP-4

Advertisement

  1. See Also
    1. Incretin Mimetic
    2. Byetta
  2. Indications
    1. Type II Diabetes Mellitus
    2. Insulin deficiency and Insulin Resistance
      1. Adjunct to Glucophage, Sulfonylureas, Glitazones
  3. Contraindications
    1. Type I Diabetes Mellitus
    2. Concurrent Insulin use
  4. Mechanism
    1. Blocks Dipeptidyl Peptidase-4 Inhibitor (DPP-4) allowing 2-3x accumulation of GLP-1
    2. Differs from Byetta: Weight neutral, no Nausea
  5. Dosing
    1. May be dosed with or without food
    2. Creatinine Clearance >50 ml/min: 100 mg once daily
    3. Creatinine Clearance 30-49 ml/min: 50 mg once daily
    4. Creatinine Clearance <30 ml/min: 25 mg once daily
  6. Efficacy
    1. Lowers HBA1C 0.6%
  7. References
    1. Jones (2007) Am Fam Physician 75:1831

sitagliptin (C1565750)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC496398
Englishsitagliptin
Spanishsitagliptina
Parent ConceptsOral hypoglycemic (C0359086), Triazole derivative (C1689939), Dipeptidyl-Peptidase IV Inhibitors (C1827106)
SourcesMSH, MTHSPL, RXNORM, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Januvia (C1702177)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC496398
EnglishJanuvia
SourcesMSH, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree